A phase I study using bortezomib with weekly idarubicin for treatment of elderly patients with acute myeloid leukemia

Leukemia Research

Volumn 37, Issue 11, 2013, Pages 1502-1508

  Howard, Dianna S ^a   Liesveld, Jane ^b   Phillips, Gordon L ^b   Hayslip, John ^a   Weiss, Heidi ^a   Jordan, Craig T ^b   Guzman, Monica L ^c  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Acute myeloid leukemia; Bortezomib; Elderly; Idarubicin

Indexed keywords

BORTEZOMIB; IDARUBICIN;

ABDOMINAL PAIN; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ANOREXIA; ARTICLE; BACTEREMIA; BRAIN HEMORRHAGE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CLINICAL ARTICLE; CONSTIPATION; DEPRESSION; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DYSPHAGIA; DYSPNEA; ELBOW DISEASE; FAINTNESS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEADACHE; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPOTENSION; HYPOXIA; JOINT SWELLING; KIDNEY FAILURE; KNEE DISEASE; MALE; MOUTH PAIN; MYALGIA; MYELODYSPLASTIC SYNDROME; NAUSEA AND VOMITING; ORAL MUCOSITIS; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; RASH; SHOULDER DISEASE; SIDE EFFECT; SORE THROAT; SWEAT; THORAX PAIN; TREATMENT DURATION; WEAKNESS;

ACUTE MYELOID LEUKEMIA; AML; BORTEZOMIB; DATA SAFETY MONITORING COMMITTEE; DLT; DOSE-LIMITING TOXICITY; DSMC; ELDERLY; ELECTROPHORETIC MOBILITY SHIFT ASSAY; EMSA; FACS; FLUORESCENCE-ACTIVATED CELL SORTING; IDARUBICIN; IKBA; INHIBITOR OF NF-KB; LEUKEMIC STEM CELL; LSC; MAXIMUM TOLERATED DOSE; MDS; MTD; MYELODYSPLASTIC SYNDROME; NF-KB; NUCLEAR FACTOR KAPPA B;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IDARUBICIN; LEUKEMIA, MYELOID, ACUTE; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PYRAZINES; REMISSION INDUCTION; SURVIVAL RATE;

EID: 84886779794     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.09.003     Document Type: Article

References (49)

1. Lowenberg B., Downing J.R., Burnett A. Acute myeloid leukemia. New Engl J Med 1999, 341:1051-1062.
2. Baudard M., Marie J.P., Cadiou M., Viguie F., Zittoun R. Acute myelogenous leukaemia in the elderly: retrospective study of 235 consecutive patients. Br J Haematol 1994, 86:82-91.
3. Bishop J.F., Matthews J.P., Young G.A., Szer J., Gillett A., Joshua D., et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood 1996, 87:1710-1717.
4. Estey E.H., Kantarjian H., Keating M.J. Therapy for acute myeloid leukemia. Hematology basic principles and practice 1995, 1014. Churchill Livingstone, New York. 2nd ed. R. Hoffman, E.J. Benz, S.J. Shattil, B. Furie, H.F. Cohen, L.E. Silberstein (Eds.).
5. Hamblin T.J. Disappointments in treating acute leukemia in the elderly. New Engl J Med 1995, 332:1712-1713.
6. Harousseau J.L. Acute myeloid leukemia in the elderly. Blood Rev 1998, 12:145-153.
7. Johnson P.R., Liu Yin J.A. Acute myeloid leukaemia in the elderly: biology and treatment. Br J Haematol 1993, 83:1-6.
8. Leith C.P., Kopecky K.J., Chen I.M., Eijdems L., Slovak M.L., McConnell T.S., et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood 1999, 94:1086-1099.
9. Leith C.P., Kopecky K.J., Godwin J., McConnell T., Slovak M.L., Chen I.M., et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 1997, 89:3323-3329.
10. Lowenberg B. Managing therapy in older adult patients with acute myeloid leukemia. Semin Hematol 2001, 38:10-16.
11. Mayer R.J., Davis R.B., Schiffer C.A., Berg D.T., Powell B.L., Schulman P., et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. New Engl J Med 1994, 331:896-903.
12. Rowe J.M., Andersen J.W., Mazza J.J., Bennett J.M., Paietta E., Hayes F.A., et al. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood 1995, 86:457-462.
13. Rowe J.M., Neuberg D., Friedenberg W., Bennett J.M., Paietta E., Makary A.Z., et al. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood 2004, 103:479-485.
14. Schiller G., Lee M. Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for older patients with acute myelogenous leukemia. Leuk Lymphoma 1997, 25:111-119.
15. Stone R.M., Berg D.T., George S.L., Dodge R.K., Paciucci P.A., Schulman P., et al. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B. New Engl J Med 1995, 332:1671-1677.
16. Taylor P.R., Reid M.M., Stark A.N., Bown N., Hamilton P.J., Proctor S.J. De novo acute myeloid leukaemia in patients over 55-years-old: a population-based study of incidence, treatment and outcome. Northern Region Haematology Group. Leukemia 1995, 9:231-237.
17. Veneri D., Zanetti F., Franchini M., Ambrosetti A., Pizzolo G. Acute myeloid leukemia in the elderly: evaluation of overall survival in 69 consecutive patients. Haematologica 2002, 87:447-448.
18. Jackson K.A., Mi T., Goodell M.A. Hematopoietic potential of stem cells isolated from murine skeletal muscle. Proc Natl Acad Sci USA 1999, 96:14482-14486.
19. Lagasse E., Connors H., Al-Dhalimy M., Reitsma M., Dohse M., Osborne L., et al. Purified hematopoietic stem cells can differentiate into hepatocytes in vivo. Nat Med 2000, 6:1229-1234.
20. Lemischka I. The power of stem cells reconsidered?. Proc Natl Acad Sci USA 1999, 96:14193-14195.
21. Phillips R.L., Ernst R.E., Brunk B., Ivanova N., Mahan M.A., Deanehan J.K., et al. The genetic program of hematopoietic stem cells. Science 2000, 288:1635-1640.
22. Blair A., Hogge D.E., Sutherland H.J. Most acute myeloid leukemia progenitor cells with long-term proliferative ability in vitro and in vivo have the phenotype CD34(+)/CD71(-)/HLA-DR. Blood 1998, 92:4325-4335.
23. Blair A., Sutherland H.J. Primitive acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo lack surface expression of c-kit (CD117). Exp Hematol 2000, 28:660-671.
24. Bonnet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997, 3:730-737.
25. Guzman M.L., Upchurch D., Grimes B., Howard D.S., Rizzieri D.A., Luger S.M., et al. Expression of tumor-suppressor genes interferon regulatory factor 1 and death-associated protein kinase in primitive acute myelogenous leukemia cells. Blood 2001, 97:2177-2179.
26. Jordan C.T., Upchurch D., Szilvassy S.J., Guzman M.L., Howard D.S., Pettigrew A.L., et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia 2000, 14:1777-1784.
27. Guan Y., Gerhard B., Hogge D.E. Detection, isolation, and stimulation of quiescent primitive leukemic progenitor cells from patients with acute myeloid leukemia (AML). Blood 2003, 101:3142-3149.
28. Guzman M.L., Neering S.J., Upchurch D., Grimes B., Howard D.S., Rizzieri D.A., et al. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 2001, 98:2301-2307.
29. Adams J., Palombella V.J., Elliott P.J. Proteasome inhibition: a new strategy in cancer treatment. Invest New Drugs 2000, 18:109-121.
30. Palombella V.J., Rando O.J., Goldberg A.L., Maniatis T. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell 1994, 78:773-785.
31. Guzman M.L., Swiderski C.F., Howard D.S., Grimes B.A., Rossi R.M., Szilvassy S.J., et al. Preferential induction of apoptosis for primary human leukemic stem cells. Proc Natl Acad Sci USA 2002, 99:16220-16225.
32. Howard D.S., Liesveld J.L., Phillips G.L., Guzman M.L., Jordan C.T. A phase I study using bortezomib with weekly idarubicin for the treatment of elderly (>60 years) and relapsed patient with acute myeloid leukemia (AML) 2008.
33. Vardiman J.W., Harris N.L., Brunning R.D. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002, 100:2292-2302.
34. Anderlini P., Benjamin R.S., Wong F.C., Kantarjian H.M., Andreeff M., Kornblau S.M., et al. Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia. J Clin Oncol 1995, 13:2827-2834.
35. Singal P.K., Iliskovic N. Doxorubicin-induced cardiomyopathy. New Engl J Med 1998, 339:900-905.
36. Bouabdallah R., Lefrere F., Rose C., Chaibi P., Harousseau J.L., Vernant J.P., et al. A phase II trial of induction and consolidation therapy of acute myeloid leukemia with weekly oral idarubicin alone in poor risk elderly patients. Leukemia 1999, 13:1491-1496.
37. Cortes J.E., Estay E., Giles F. Phase I study of bortezomib (PS-341, Velcadetm), a proteasome inhibitor, in patients with refractory or relapsed acute leukemias and myelodysplastic syndromes (Abstract #2201) 2002.
38. Orlowski R.Z., Stinchcombe T.E., Mitchell B.S., Shea T.C., Baldwin A.S., Stahl S., et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 2002, 20:4420-4427.
39. Richardson P.G., Barlogie B., Berenson J., Singhal S., Jagannath S., Irwin D., et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. New Engl J Med 2003, 348:2609-2617.
40. Boland M.P., Foster S.J., O'Neill L.A. Daunorubicin activates NFkappaB and induces kappaB-dependent gene expression in HL-60 promyelocytic and Jurkat T lymphoma cells. J Biol Chem 1997, 272:12952-12960.
41. Laurent G., Jaffrezou J.P. Signaling pathways activated by daunorubicin. Blood 2001, 98:913-924.
42. Dohner H., Estey E.H., Amadori S., Appelbaum F.R., Buchner T., Burnett A.K., et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010, 115:453-474.
43. Cheson B.D., Bennett J.M., Kopecky K.J., Buchner T., Willman C.L., Estey E.H., et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003, 21:4642-4649.
44. Byrd J.C., Mrozek K., Dodge R.K., Carroll A.J., Edwards C.G., Arthur D.C., et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002, 100:4325-4336.
45. Natarajan-Ame S., Park S., Ades L., Vey N., Guerci-Bresler A., Cahn J.Y., et al. Bortezomib combined with low-dose cytarabine in Intermediate-2 and high risk myelodysplastic syndromes. A phase I/II Study by the GFM. Br J Haematol 2012, 158:232-237.
46. Advani A. A Phase 1 Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in combination with bortezomib for relapsed/refractory acute myeloid leukemia. 54th ASH annual meeting and exposition 2012, Abstract 3595.
47. Attar E.C., De Angelo D.J., Supko J.G., D'Amato F., Zahrieh D., Sirulnik A., et al. Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia. Clin Cancer Res 2008, 14:1446-1454.
48. Attar E.C., Johnson J.L., Amrein P.C., Lozanski G., Wadleigh M., Deangelo D.J., et al. Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) Study 10502. J Clin Oncol 2012, 31:923-929.
49. Horton T. A phase 2 study of bortezomib combined with reinduction chemotherapy in children and young adults with recurrent, refractory or secondary acute myeloid leukemia: a Children's Oncology Group (COG) study. 54th ASH annual meeting and exposition 2012, Abstract 3580.